Drug
Tarlatamab
Tarlatamab: highest development phase Phase 3, developed by Amgen, LEO Pharma. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Amgen, LEO Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tarlatamab NCT06211036 | Phase 3 | Extensive-Stage Small-Cell Lung Cancer |
| Tarlatamab NCT07243470 | Phase 1/2 | Glioma |
| Tarlatamab NCT03319940 | Phase 1 | Small Cell Lung Carcinoma |
Latest
No recent events.
Follow Tarlatamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.